Biotech: Page 54
-
Courtesy of Biohaven Ltd.
Biohaven starts life as new company following Pfizer buyout
Spun out as part of Pfizer’s $11.6 billion acquisition, the biotech retains a pipeline of experimental neuroscience drugs and holds $258 million in cash.
By Ned Pagliarulo • Oct. 5, 2022 -
Spencer Platt via Getty Images
KalVista stops work on rare disease drug over safety concerns
The biotech terminated a Phase 2 study after treatment led to serious liver enzyme elevations in multiple patients with hereditary angioedema.
By Ned Pagliarulo • Oct. 4, 2022 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Permission granted by Cellarity
A Flagship startup secures $121M in new funding
Cellarity is the second Flagship company in as many months to raise a Series C round instead of filing to go public.
By Gwendolyn Wu • Oct. 4, 2022 -
Permission granted by Spark Therapeutics
Former Spark CEO Marrazzo joins epigenetics startup’s board
Chroma Medicine, which launched last year with $125 million in funding, has drawn several high-profile biotech leaders, including ex-Alnylam CEO John Maraganore and deal maven George Golumbeski.
By Ned Pagliarulo • Oct. 4, 2022 -
Permission granted by Incyte
Incyte, branching out in dermatology, to buy startup Villaris
The acquisition, Incyte’s first of an entire company, hands the pharmaceutical company a potentially long lasting treatment for the skin disease vitiligo.
By Gwendolyn Wu • Oct. 3, 2022 -
Spencer Platt via Getty Images
Myovant rejects $2.4B buyout offer from Japanese majority owner
The biotech said the proposed offer “significantly undervalues” the company, but that it’s open to considering a higher bid.
By Christopher Newman • Oct. 3, 2022 -
Lisa Maree Williams via Getty Images
AstraZeneca to acquire gene editing biotech LogicBio
Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting. The buyout deal represents a premium of over 600%.
By Delilah Alvarado • Oct. 3, 2022 -
Dr_Microbe via Getty Images
Solid Bio yields to Sarepta on Duchenne with plans for merger, R&D shakeup
The biotech, which fell behind Sarepta in developing a Duchenne gene therapy, will merge with AavantiBio, a startup run by a former Sarepta executive.
By Ben Fidler • Sept. 30, 2022 -
Anne Callahan/BioPharma Dive
Sponsored by TD2 Precision Oncology[PODCAST] Evolution and Innovation in Oncology Therapeutics Development
The “Evolution and Innovation in Oncology Therapeutics Development” podcast series explores the role of multi-biomarkers in precision oncology.
By BioPharma Dive's studioID • Updated Sept. 11, 2023 -
Permission granted by Amylyx Pharmaceuticals
ALS drug developmentALS drug approved by FDA in closely watched decision, marking win for patients, developer
The drug, which will be sold as Relyvrio, showed modest benefits in function and survival in testing. It also became the latest test of the FDA's flexibility toward new therapies for neurological disorders.
By Jacob Bell • Updated Sept. 30, 2022 -
alvarez via Getty Images
Sudo joins a wave of startups taking aim at Bristol Myers’ new skin disease drug
The startup, which emerged Wednesday with $37 million in funding, is the latest company trying to top Bristol Myers’ TYK2 inhibitor Sotyktu.
By Gwendolyn Wu • Sept. 28, 2022 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
New Alzheimer's drugsIn surprise result, Alzheimer’s drug from Eisai, Biogen shows benefit in large trial
The companies’ drug lecanemab met all of its goals in the Phase 3 study. The data were a significant finding and provided stronger support for a much-debated hypothesis for treating Alzheimer’s.
By Jonathan Gardner • Updated Sept. 27, 2022 -
Courtesy of Vertex Pharmaceuticals
Vertex given green light to seek US approval of CRISPR-based therapy
The company and its development partner, CRISPR Therapeutics, will begin submitting a rolling application in November. The blood disease treatment is the first of its kind to near an FDA review.
By Jacob Bell • Sept. 27, 2022 -
Courtesy of Scribe Therapeutics
Sanofi partners with Scribe to gain gene editing tools for cell therapy work
The California biotech will receive $25 million upfront from Sanofi, which plans to use Scribe’s platform to edit natural killer cells for cancer treatment.
By Ned Pagliarulo • Sept. 27, 2022 -
Permission granted by Ethan Perlstein and Klein Lab at UCSF
Q&APerlara CEO Ethan Perlstein on reviving a biotech and building a ‘Y Combinator of rare diseases’
The CEO resuscitated the sector’s first public benefit corporation during the pandemic, building an unusually transparent model for biotechs. Now, he’s spun out a startup and is planning for more.
By Gwendolyn Wu • Sept. 27, 2022 -
Permission granted by Prime Medicine
Prime Medicine becomes the next high-profile biotech to test IPO waters
The startup, which launched last year with $315 million in funding and plans to advance a new form of gene editing, is one of the first big venture-backed biotechs in several months to seek an IPO.
By Ben Fidler • Sept. 26, 2022 -
Jolygon via Getty Images
AstraZeneca gives up on Ionis’ RNA drug for heart disease
The British drugmaker decided the medicine, which works similarly to Novartis’s Leqvio, wasn’t potent enough to justify further testing.
By Jonathan Gardner • Sept. 23, 2022 -
Elizabeth Regan/BioPharma Dive
Servier cuts ties with Allogene, ending complex CAR-T partnership
The French drugmaker terminated a nearly decade-old deal that helped Allogene emerge as the sector's largest "off-the-shelf" cell therapy developer.
By Ben Fidler • Sept. 22, 2022 -
Md Saiful Islam Khan via Getty Images
GSK buys into Spero’s comeback plan
The British drugmaker is investing in Spero Therapeutics and acquiring most of the rights to an oral antibiotic the FDA previously rejected, but could approve if it succeeds in a new Phase 3 trial.
By Ben Fidler • Sept. 22, 2022 -
Design Cells via Getty Images
Cell therapy startup Carisma merges with troubled Sesen in bid for Wall Street
The deal results from a strategic review Sesen, formerly known as Eleven Biotherapeutics, undertook after the FDA rejected its top drug last year.
By Gwendolyn Wu • Sept. 21, 2022 -
Courtesy of University of Copenhagen
Foundation behind Novo Nordisk to invest $200M in building quantum research ‘powerhouse’
The grant is one of the Novo Nordisk Foundation’s largest and will fund a 12-year research collaboration to construct a quantum computer dedicated to the life sciences.
By Ned Pagliarulo • Sept. 21, 2022 -
gorodenkoff via Getty Images
Vesalius Therapeutics, a buzzy, Flagship-backed startup, cuts jobs six months after public launch
When the company debuted in March, it announced plans to hire 200 employees over two years. Now, it’s laid off nearly half its staff in a year when the biotech sector has experienced a sharp market downturn.
By Gwendolyn Wu • Sept. 19, 2022 -
yodiyim via Getty Images
Theravance, flush with royalty cash, buys shares from GSK
The planned transaction will further unwind the respiratory disease company’s relationship with GSK, which dates back two decades.
By Jonathan Gardner • Sept. 19, 2022 -
Dr_Microbe via Getty Images
Alnylam, Regeneron to advance NASH drug after early signs of potential
A gene discovery four years ago led to a partnership between the companies, which plan to start a Phase 2 study later this year after encouraging early data.
By Ned Pagliarulo • Sept. 15, 2022 -
Third Harmonic boosts biotech with sector’s top IPO in four months
The startup’s $185 million initial public offering is the largest for the sector since early May and potentially a sign of renewed investor interest in young biotechs.
By Ben Fidler • Sept. 15, 2022
Previous
